Last reviewed · How we verify
ABP 692
ABP 692 is a monoclonal antibody that targets amyloid-beta protofibrils to reduce amyloid pathology in Alzheimer's disease.
ABP 692 is a monoclonal antibody that targets amyloid-beta protofibrils to reduce amyloid pathology in Alzheimer's disease. Used for Early symptomatic Alzheimer's disease (mild cognitive impairment or mild dementia stage).
At a glance
| Generic name | ABP 692 |
|---|---|
| Sponsor | Amgen |
| Drug class | Monoclonal antibody (anti-amyloid-beta) |
| Target | Amyloid-beta protofibrils |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
ABP 692 binds to amyloid-beta protofibrils, which are believed to be toxic intermediates in Alzheimer's disease pathogenesis. By targeting these specific conformations of amyloid-beta, the drug aims to reduce neuroinflammation and slow cognitive decline. This mechanism is distinct from other anti-amyloid approaches that target different forms of amyloid-beta aggregates.
Approved indications
- Early symptomatic Alzheimer's disease (mild cognitive impairment or mild dementia stage)
Common side effects
- Amyloid-related imaging abnormalities (ARIA) - microhemorrhages
- Amyloid-related imaging abnormalities (ARIA) - edema
- Infusion reactions
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ABP 692 CI brief — competitive landscape report
- ABP 692 updates RSS · CI watch RSS
- Amgen portfolio CI